论文部分内容阅读
目的:比较细胞DNA倍体分析技术与宫颈液基细胞学联合HPV DNA检测在宫颈癌前病变诊断中的应用价值。方法:将1 068例门诊患者随机分为2组,分别进行细胞DNA倍体分析或宫颈液基细胞学联合HPV DNA检测,比较两种检测方案检测宫颈癌前病变的准确性。结果:检测阳性率细胞DNA倍体分析组为7.68%,宫颈液基细胞学联合HPV检测组为6.93%,两组比较差异无统计学意义(P>0.05)。以CINⅠ为癌前病变标准,细胞DNA倍体分析组筛查阳性的病例癌前病变符合率为75.61%,宫颈液基细胞学联合HPV检测组为54.05%,两组比较差异有统计学意义(P“,”Objective:To compare the clinical application values of DNA ploidy analysis of cervical cells and Thinprep cytologic test combined with HPV detection for diagnosis of cervical precancerous lesion.Methods:A total of 1 068 patients from outpatient department of the hospital were randomly divided into two groups,then the patients in the two groups received DNA ploidy analysis of cervical cells and Thinprep cytologic test combined with HPV detection,respectively;the accuracies of the two methods for diagnosis of cervical precancerous lesion were compared.Results:The positive rates in DNA ploidy analysis group and joint detection group were 7.68% and 6.93%,respectively,there was no statistically significant difference between the two groups(P>0.05).Taking cervical intraepithelial neoplasia(CIN) Ⅰ as the criterion of cervical precancerous lesion,the coincidence rates in DNA ploidy analysis group and joint detection group were 75.61% and 54.05%,respectively,there was statistically significant difference between the two groups(P<0.05).Conclusion:The positive rates of DNA ploidy analysis and joint detection for screening cervical lesions are approximate,but the accuracy of DNA ploidy analysis for screening CIN is higher.